James Emmett Herndon II, PhD

Print

email this


Associate Professor of Biostatistics and Bionformatics
Department:
Biostatistics & Bioinformatics
Address:
8034 Hock Plaza
2424 Erwin Road
Durham, NC 27705
Office Telephone:
(919) 668-8145
Training:
  • PhD, University of North Carolina at Chapel Hill, 1988
Research Interests:
Current research interests have application to the design and analysis of cancer clinical trials. Specifically, interests include the use of time-dependent covariables within survival models, the design of phase II cancer clinical trials which minimize some of the logistical problems associated with their conduct, and the analysis of longitudinal studies with informative censoring (in particular, quality of life studies of patients with advanced cancer).
Representative Publications:
  • Reardon, DA; Desjardins, A; Vredenburgh, JJ; Gururangan, S; Friedman, AH; Herndon, JE; Marcello, J; Norfleet, JA; McLendon, RE; Sampson, JH; Friedman, HS. Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. Journal of Neuro-Oncology. 2010;96:219-230.  Abstract
  • Abernethy, AP; Barbour, SY; Uronis, H; Zafar, SY; Coan, A; Rowe, K; Pupa, MR; Wheeler, JL; Herndon, JE. Quality management of potential chemotherapy-induced neutropenic complications: evaluation of practice in an academic medical center. Supportive Care in Cancer. 2009;17:735-744.  Abstract
  • Abernethy, AP; Herndon, JE; Wheeler, JL; Day, JM; Hood, L; Patwardhan, M; Shaw, H; Lyerly, HK. Feasibility and acceptability to patients of a longitudinal system for evaluating cancer-related symptoms and quality of life: pilot study of an e/Tablet data-collection system in academic oncology. Journal of Pain and Symptom Management. 2009;37:1027-1038.  Abstract
  • Affronti, ML; Heery, CR; Herndon, JE; Rich, JN; Reardon, DA; Desjardins, A; Vredenburgh, JJ; Friedman, AH; Bigner, DD; Friedman, HS. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy. Cancer. 2009;115:3501-3511.  Abstract
  • Alfano, CM; Day, JM; Katz, ML; Herndon, JE; Bittoni, MA; Oliveri, JM; Donohue, K; Paskett, ED. Exercise and dietary change after diagnosis and cancer-related symptoms in long-term survivors of breast cancer: CALGB 79804. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer. 2009;18:128-133.  Abstract
  • Birchard, KR; Hoang, JK; Herndon, JE; Patz, EF. Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival. Cancer. 2009;115:581-586.  Abstract
  • Dupont, A; Wheeler, J; Herndon, JE; Coan, A; Zafar, SY; Hood, L; Patwardhan, M; Shaw, HS; Lyerly, HK; Abernethy, AP. Use of tablet personal computers for sensitive patient-reported information. The Journal of Supportive Oncology. 2009;7:91-97.  Abstract
  • Katz, ML; Donohue, KA; Alfano, CM; Day, JM; Herndon, JE; Paskett, ED. Cancer surveillance behaviors and psychosocial factors among long-term survivors of breast cancer. Cancer and Leukemia Group B 79804. Cancer. 2009;115:480-488.  Abstract
  • Paskett, E; Herndon, J; Donohue, K; Naughton, M; Grubbs, S; Pavy, M; Hensley, M; Stark, N; Kornblith, A; Bittoni, M; for Cancer and Leukemia Group B. Health-related quality of life in long-term breast cancer survivors: differences by adjuvant chemotherapy dose in Cancer and Leukemia Group B study 8541. Cancer. 2009;115:1109-1120.  Abstract
  • Quinn, JA; Jiang, SX; Carter, J; Reardon, DA; Desjardins, A; Vredenburgh, JJ; Rich, JN; Gururangan, S; Friedman, AH; Bigner, DD; Sampson, JH; McLendon, RE; Herndon, JE; Threatt, S; Friedman, HS. Phase II trial of Gliadel plus O6-benzylguanine in adults with recurrent glioblastoma multiforme. Clinical Cancer Research. 2009;15:1064-1068.  Abstract
  • Quinn, JA; Jiang, SX; Reardon, DA; Desjardins, A; Vredenburgh, JJ; Friedman, AH; Sampson, JH; McLendon, RE; Herndon, JE; Friedman, HS. Phase II trial of temozolomide (TMZ) plus irinotecan (CPT-11) in adults with newly diagnosed glioblastoma multiforme before radiotherapy. Journal of Neuro-Oncology. 2009;95:393-400.  Abstract
  • Quinn, JA; Jiang, SX; Reardon, DA; Desjardins, A; Vredenburgh, JJ; Gururangan, S; Sampson, JH; McLendon, RE; Herndon, JE; Friedman, HS. Phase 1 trial of temozolomide plus irinotecan plus O6-benzylguanine in adults with recurrent malignant glioma. Cancer. 2009;115:2964-2970.  Abstract
  • Quinn, JA; Jiang, SX; Reardon, DA; Desjardins, A; Vredenburgh, JJ; Rich, JN; Gururangan, S; Friedman, AH; Bigner, DD; Sampson, JH; McLendon, RE; Herndon, JE; Walker, A; Friedman, HS. Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. Journal of Clinical Oncology. 2009;27:1262-1267.  Abstract
  • Reardon, DA; Egorin, MJ; Desjardins, A; Vredenburgh, JJ; Beumer, JH; Lagattuta, TF; Gururangan, S; Herndon, JE; Salvado, AJ; Friedman, HS. Phase I pharmacokinetic study of the vascular endothelial growth factor receptor tyrosine kinase inhibitor vatalanib (PTK787) plus imatinib and hydroxyurea for malignant glioma. Cancer. 2009;115:2188-2198.  Abstract
  • Yan, H; Parsons, DW; Jin, G; McLendon, R; Rasheed, BA; Yuan, W; Kos, I; Batinic-Haberle, I; Jones, S; Riggins, GJ; Friedman, H; Friedman, A; Reardon, D; Herndon, J; Kinzler, KW; Velculescu, VE; Vogelstein, B; Bigner, DD. IDH1 and IDH2 mutations in gliomas. New England Journal of Medicine. 2009;360:765-773.  Abstract
  • Abernethy, AP; Herndon, JE; Wheeler, JL; Patwardhan, M; Shaw, H; Lyerly, HK; Weinfurt, K. Improving Health Care Efficiency and Quality Using Tablet Personal Computers to Collect Research-Quality, Patient-Reported Data. Health Services Research. 2008;  Abstract
  • Arnold, SD; Forman, LM; Brigidi, BD; Carter, KE; Schweitzer, HA; Quinn, HE; Guill, AB; Herndon, JE; Raynor, RH. Evaluation and characterization of generalized anxiety and depression in patients with primary brain tumors. Neuro-Oncology. 2008;10:171-181.  Abstract
  • Bogart, JA; Watson, D; McClay, EF; Evans, L; Herndon, JE; Laurie, F; Seagren, SL; Fitzgerald, TJ; Vokes, E; Green, MR. Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: analysis of CALGB phase III trial 9235. Lung Cancer. 2008;62:92-98.  Abstract
  • Burfeind, WR; Tong, BC; O'Branski, E; Herndon, JE; Toloza, EM; D'Amico, TA; Harpole, LH; Harpole, DH. Quality of life outcomes are equivalent after lobectomy in the elderly. Journal of Thoracic and Cardiovascular Surgery. 2008;136:597-604.  Abstract
  • Desjardins, A; Reardon, DA; Herndon, JE; Marcello, J; Quinn, JA; Rich, JN; Sathornsumetee, S; Gururangan, S; Sampson, J; Bailey, L; Bigner, DD; Friedman, AH; Friedman, HS; Vredenburgh, JJ. Bevacizumab plus irinotecan in recurrent WHO grade 3 malignant gliomas. Clinical Cancer Research. 2008;14:7068-7073.  Abstract
  • Graziano, SL; Herndon, JE; Socinski, MA; Wang, X; Watson, D; Vokes, E; Green, MR; Cancer and Leukemia Group B. Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901. Journal of Thoracic Oncology. 2008;3:158-162.  Abstract
  • Greenberg, JA; Shibata, D; Herndon, JE; Steele, GD; Mayer, R; Bleday, R. Local excision of distal rectal cancer: an update of cancer and leukemia group B 8984. Diseases of the Colon and Rectum. 2008;51:1185-1191.  Abstract
  • Herndon, JE; Kornblith, AB; Holland, JC; Paskett, ED. Patient education level as a predictor of survival in lung cancer clinical trials. Journal of Clinical Oncology. 2008;26:4116-4123.  Abstract
  • Hoang, JK; Hoagland, LF; Coleman, RE; Coan, AD; Herndon, JE; Patz, EF. Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. Journal of Clinical Oncology. 2008;26:1459-1464.  Abstract
  • Lamont, EB; Herndon, JE; Weeks, JC; Henderson, IC; Lilenbaum, R; Schilsky, RL; Christakis, NA; Cancer and Leukemia Group B. Measuring clinically significant chemotherapy-related toxicities using Medicare claims from Cancer and Leukemia Group B (CALGB) trial participants. Medical Care. 2008;46:303-308.  Abstract
  • Ochiai, H; Archer, GE; Herndon, JE; Kuan, CT; Mitchell, DA; Bigner, DD; Pastan, IH; Sampson, JH. EGFRvIII-targeted immunotoxin induces antitumor immunity that is inhibited in the absence of CD4+ and CD8+ T cells. Cancer Immunology Immunotherapy. 2008;57:115-121.  Abstract
  • Oliveri, JM; Day, JM; Alfano, CM; Herndon, JE; Katz, ML; Bittoni, MA; Donohue, K; Paskett, ED. Arm/hand swelling and perceived functioning among breast cancer survivors 12 years post-diagnosis: CALGB 79804. Journal of Cancer Survivorship. 2008;2:233-242.  Abstract
  • Paskett, ED; Herndon, JE; Day, JM; Stark, NN; Winer, EP; Grubbs, SS; Pavy, MD; Shapiro, CL; List, MA; Hensley, ML; Naughton, MA; Kornblith, AB; Habin, KR; Fleming, GF; Bittoni, MA; Cancer and Leukemia Group B. Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer. 2008;17:1108-1120.  Abstract
  • Reardon, DA; Desjardins, A; Vredenburgh, JJ; Sathornsumetee, S; Rich, JN; Quinn, JA; Lagattuta, TF; Egorin, MJ; Gururangan, S; McLendon, R; Herndon, JE; Friedman, AH; Salvado, AJ; Friedman, HS. Safety and pharmacokinetics of dose-intensive imatinib mesylate plus temozolomide: phase 1 trial in adults with malignant glioma. Neuro-Oncology. 2008;10:330-340.  Abstract
  • Reardon, DA; Zalutsky, MR; Akabani, G; Coleman, RE; Friedman, AH; Herndon, JE; McLendon, RE; Pegram, CN; Quinn, JA; Rich, JN; Vredenburgh, JJ; Desjardins, A; Guruangan, S; Boulton, S; Raynor, RH; Dowell, JM; Wong, TZ; Zhao, XG; Friedman, HS; Bigner, DD. A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro-Oncology. 2008;10:182-189.  Abstract
  • Sampson, JH; Akabani, G; Archer, GE; Berger, MS; Coleman, RE; Friedman, AH; Friedman, HS; Greer, K; Herndon, JE; Kunwar, S; McLendon, RE; Paolino, A; Petry, NA; Provenzale, JM; Reardon, DA; Wong, TZ; Zalutsky, MR; Pastan, I; Bigner, DD. Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro-Oncology. 2008;10:320-329.  Abstract
  • Sathornsumetee, S; Cao, Y; Marcello, JE; Herndon, JE; McLendon, RE; Desjardins, A; Friedman, HS; Dewhirst, MW; Vredenburgh, JJ; Rich, JN. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. Journal of Clinical Oncology. 2008;26:271-278.  Abstract
  • Schmittling, RJ; Archer, GE; Mitchell, DA; Heimberger, A; Pegram, C; Herndon, JE; Friedman, HS; Bigner, DD; Sampson, JH. Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. Journal of Immunological Methods. 2008;339:74-81.  Abstract
  • Stinchcombe, TE; Mauer, AM; Hodgson, LD; Herndon, JE; Lynch, TJ; Green, MR; Vokes, EE; Cancer and Leukemia Group B. Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430. Journal of Thoracic Oncology. 2008;3:1301-1307.  Abstract
  • Strauss, GM; Herndon, JE; Maddaus, MA; Johnstone, DW; Johnson, EA; Harpole, DH; Gillenwater, HH; Watson, DM; Sugarbaker, DJ; Schilsky, RL; Vokes, EE; Green, MR. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. Journal of Clinical Oncology. 2008;26:5043-5051.  Abstract
  • Zafar, SY; Abernethy, AP; Abbott, DH; Grambow, SC; Marcello, JE; Herndon, JE; Rowe, KL; Kolimaga, JT; Zullig, LL; Patwardhan, MB; Provenzale, DT. Comorbidity, age, race and stage at diagnosis in colorectal cancer: a retrospective, parallel analysis of two health systems. BMC Cancer. 2008;8:345.  Abstract
  • Badruddoja, MA; Penne, K; Desjardins, A; Reardon, DA; Rich, JN; Quinn, JA; Sathornsumetee, S; Friedman, AH; Bigner, DD; Herndon, JE; Cahill, A; Friedman, HS; Vredenburgh, JJ. Phase II study of Cloretazine for the treatment of adults with recurrent glioblastoma multiforme. Neuro-Oncology. 2007;9:70-74.  Abstract
  • Desjardins, A; Quinn, JA; Vredenburgh, JJ; Sathornsumetee, S; Friedman, AH; Herndon, JE; McLendon, RE; Provenzale, JM; Rich, JN; Sampson, JH; Gururangan, S; Dowell, JM; Salvado, A; Friedman, HS; Reardon, DA. Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. Journal of Neuro-Oncology. 2007;83:53-60.  Abstract
  • Gauger, J; Patz, EF; Coleman, RE; Herndon, JE. Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrence. Journal of Thoracic Oncology. 2007;2:499-505.  Abstract
  • Gururangan, S; Fisher, MJ; Allen, JC; Herndon, JE; Quinn, JA; Reardon, DA; Vredenburgh, JJ; Desjardins, A; Phillips, PC; Watral, MA; Krauser, JM; Friedman, AH; Friedman, HS. Temozolomide in children with progressive low-grade glioma. Neuro-Oncology. 2007;9:161-168.  Abstract
  • Hoagland, LF; Campa, MJ; Gottlin, EB; Herndon, JE; Patz, EF. Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer. Cancer. 2007;110:2260-2268.  Abstract
  • Linardic, CM; Naini, S; Herndon, JE; Kesserwan, C; Qualman, SJ; Counter, CM. The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence. Cancer Research. 2007;67:6691-6699.  Abstract
  • Loewen, GM; Watson, D; Kohman, L; Herndon, JE; Shennib, H; Kernstine, K; Olak, J; Mador, MJ; Harpole, D; Sugarbaker, D; Green, M; Cancer and Leukemia Group B. Preoperative exercise Vo2 measurement for lung resection candidates: results of Cancer and Leukemia Group B Protocol 9238. Journal of Thoracic Oncology. 2007;2:619-625.  Abstract
  • McLendon, RE; Akabani, G; Friedman, HS; Reardon, DA; Cleveland, L; Cokgor, I; Herndon, JE; Wikstrand, C; Boulton, ST; Friedman, AH; Bigner, DD; Zalutsky, MR. Tumor resection cavity administered iodine-131-labeled antitenascin 81C6 radioimmunotherapy in patients with malignant glioma: neuropathology aspects. Nuclear Medicine and Biology. 2007;34:405-413.  Abstract
  • Patz, EF; Campa, MJ; Gottlin, EB; Kusmartseva, I; Guan, XR; Herndon, JE. Panel of serum biomarkers for the diagnosis of lung cancer. Journal of Clinical Oncology. 2007;25:5578-5583.  Abstract
  • Riedel, RF; Andrews, C; Garst, J; Dunphy, F; Herndon, JE; Blackwell, S; Barbour, S; Crawford, J. A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer. Journal of Thoracic Oncology. 2007;2:520-525.  Abstract
  • Rocha-Lima, CM; Herndon, JE; Lee, ME; Atkins, JN; Mauer, A; Vokes, E; Green, MR; Cancer and Leukemia Group B. Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902. Annals of Oncology. 2007;18:331-337.  Abstract
  • Sampson, JH; Raghavan, R; Brady, ML; Provenzale, JM; Herndon, JE; Croteau, D; Friedman, AH; Reardon, DA; Coleman, RE; Wong, T; Bigner, DD; Pastan, I; RodrĂ­guez-Ponce, MI; Tanner, P; Puri, R; Pedain, C. Clinical utility of a patient-specific algorithm for simulating intracerebral drug infusions. Neuro-Oncology. 2007;9:343-353.  Abstract
  • Swanson, SJ; Herndon, JE; D'Amico, TA; Demmy, TL; McKenna, RJ; Green, MR; Sugarbaker, DJ. Video-assisted thoracic surgery lobectomy: report of CALGB 39802--a prospective, multi-institution feasibility study. Journal of Clinical Oncology. 2007;25:4993-4997.  Abstract
  • Vokes, EE; Herndon, JE; Kelley, MJ; Cicchetti, MG; Ramnath, N; Neill, H; Atkins, JN; Watson, DM; Akerley, W; Green, MR; Cancer and Leukemia Group B. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. Journal of Clinical Oncology. 2007;25:1698-1704.  Abstract
  • Vredenburgh, JJ; Desjardins, A; Herndon, JE; Dowell, JM; Reardon, DA; Quinn, JA; Rich, JN; Sathornsumetee, S; Gururangan, S; Wagner, M; Bigner, DD; Friedman, AH; Friedman, HS. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clinical Cancer Research. 2007;13:1253-1259.  Abstract
  • Vredenburgh, JJ; Desjardins, A; Herndon, JE; Marcello, J; Reardon, DA; Quinn, JA; Rich, JN; Sathornsumetee, S; Gururangan, S; Sampson, J; Wagner, M; Bailey, L; Bigner, DD; Friedman, AH; Friedman, HS. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. Journal of Clinical Oncology. 2007;25:4722-4729.  Abstract
  • Allen, MS; Darling, GE; Pechet, TT; Mitchell, JD; Herndon, JE; Landreneau, RJ; Inculet, RI; Jones, DR; Meyers, BF; Harpole, DH; Putnam, JB; Rusch, VW; ACOSOG Z0030 Study Group. Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. Annals of Thoracic Surgery. 2006;81:1013-1019.  Abstract
  • Anscher, MS; Garst, J; Marks, LB; Larrier, N; Dunphy, F; Herndon, JE; Clough, R; Marino, C; Vujaskovic, Z; Zhou, S; Dewhirst, MW; Shafman, TD; Crawford, J. Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury. International Journal of Radiation: Oncology - Biology - Physics. 2006;66:477-482.  Abstract
  • Blackstock, AW; Herndon, JE; Paskett, ED; Miller, AA; Lathan, C; Niell, HB; Socinski, MA; Vokes, EE; Green, MR; Cancer and Leukemia Group B. Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B. Journal of Clinical Oncology. 2006;24:407-412.  Abstract
  • Cornett, WR; McCall, LM; Petersen, RP; Ross, MI; Briele, HA; Noyes, RD; Sussman, JJ; Kraybill, WG; Kane, JM; Alexander, HR; Lee, JE; Mansfield, PF; Pingpank, JF; Winchester, DJ; White, RL; Chadaram, V; Herndon, JE; Fraker, DL; Tyler, DS; American College of Surgeons Oncology Group Trial Z0020. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. Journal of Clinical Oncology. 2006;24:4196-4201.  Abstract
  • D'Amico, TA; Brooks, KR; Joshi, MB; Conlon, D; Herndon, J; Petersen, RP; Harpole, DH. Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection. Annals of Thoracic Surgery. 2006;81:1982-1987.  Abstract
  • Fecci, PE; Mitchell, DA; Whitesides, JF; Xie, W; Friedman, AH; Archer, GE; Herndon, JE; Bigner, DD; Dranoff, G; Sampson, JH. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Research. 2006;66:3294-3302.  Abstract
  • Garst, J; Herndon, JE; Shafman, T; Campagna, L; Blackwell, S; Padilla, K; Bjurstrom, T; Andrews, C; Maravich-May, D; Anderson, E; Crawford, J. A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer. Clinical Drug Investigation. 2006;26:257-266.  Abstract
  • Jaklitsch, MT; Herndon, JE; DeCamp, MM; Richards, WG; Kumar, P; Krasna, MJ; Green, MR; Sugarbaker, DJ. Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935. Journal of Surgical Oncology. 2006;94:599-606.  Abstract
  • Kemeny, NE; Niedzwiecki, D; Hollis, DR; Lenz, HJ; Warren, RS; Naughton, MJ; Weeks, JC; Sigurdson, ER; Herndon, JE; Zhang, C; Mayer, RJ. Hepatic arterial infusion versus systemic therapy for hepatic metastases from colorectal cancer: a randomized trial of efficacy, quality of life, and molecular markers (CALGB 9481). Journal of Clinical Oncology. 2006;24:1395-1403.  Abstract
  • Kornblith, AB; Dowell, JM; Herndon, JE; Engelman, BJ; Bauer-Wu, S; Small, EJ; Morrison, VA; Atkins, J; Cohen, HJ; Holland, JC. Telephone monitoring of distress in patients aged 65 years or older with advanced stage cancer: a cancer and leukemia group B study. Cancer. 2006;107:2706-2714.  Abstract
  • Kuan, CT; Wakiya, K; Dowell, JM; Herndon, JE; Reardon, DA; Graner, MW; Riggins, GJ; Wikstrand, CJ; Bigner, DD. Glycoprotein nonmetastatic melanoma protein B, a potential molecular therapeutic target in patients with glioblastoma multiforme. Clinical Cancer Research. 2006;12:1970-1982.  Abstract
  • Lamont, EB; Herndon, JE; Weeks, JC; Henderson, IC; Earle, CC; Schilsky, RL; Christakis, NA; Cancer and Leukemia Group B. Measuring disease-free survival and cancer relapse using Medicare claims from CALGB breast cancer trial participants (companion to 9344). Journal of National Cancer Institute. 2006;98:1335-1338.  Abstract
  • Maxwell, JA; Johnson, SP; Quinn, JA; McLendon, RE; Ali-Osman, F; Friedman, AH; Herndon, JE; Bierau, K; Bigley, J; Bigner, DD; Friedman, HS. Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma. Molecular Cancer Therapeutics. 2006;5:2531-2539.  Abstract
  • Reardon, DA; Akabani, G; Coleman, RE; Friedman, AH; Friedman, HS; Herndon, JE; McLendon, RE; Pegram, CN; Provenzale, JM; Quinn, JA; Rich, JN; Vredenburgh, JJ; Desjardins, A; Gururangan, S; Badruddoja, M; Dowell, JM; Wong, TZ; Zhao, XG; Zalutsky, MR; Bigner, DD. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. Journal of Clinical Oncology. 2006;24:115-122.  Abstract
  • Reardon, DA; Quinn, JA; Akabani, G; Coleman, RE; Friedman, AH; Friedman, HS; Herndon, JE; McLendon, RE; Pegram, CN; Provenzale, JM; Dowell, JM; Rich, JN; Vredenburgh, JJ; Desjardins, A; Sampson, JH; Gururangan, S; Wong, TZ; Badruddoja, MA; Zhao, XG; Bigner, DD; Zalutsky, MR. Novel human IgG2b/murine chimeric antitenascin monoclonal antibody construct radiolabeled with 131I and administered into the surgically created resection cavity of patients with malignant glioma: phase I trial results. Journal of Nuclear Medicine. 2006;47:912-918.  Abstract
  • Reardon, DA; Quinn, JA; Vredenburgh, JJ; Gururangan, S; Friedman, AH; Desjardins, A; Sathornsumetee, S; Herndon, JE; Dowell, JM; McLendon, RE; Provenzale, JM; Sampson, JH; Smith, RP; Swaisland, AJ; Ochs, JS; Lyons, P; Tourt-Uhlig, S; Bigner, DD; Friedman, HS; Rich, JN. Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clinical Cancer Research. 2006;12:860-868.  Abstract
  • Riedel, RF; Crawford, J; Dunphy, F; Herndon, JE; Garst, J; Kelley, MJ. Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer. Lung Cancer. 2006;54:431-432.  Abstract
  • Vlahovic, G; Rabbani, ZN; Herndon, JE; Dewhirst, MW; Vujaskovic, Z. Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation. British Journal of Cancer. 2006;95:1013-1019.  Abstract
  • Wilke, LG; McCall, LM; Posther, KE; Whitworth, PW; Reintgen, DS; Leitch, AM; Gabram, SG; Lucci, A; Cox, CE; Hunt, KK; Herndon, JE; Giuliano, AE. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Annals of Surgical Oncology. 2006;13:491-500.  Abstract
  • Akerley, W; Herndon, JE; Lyss, AP; Choy, H; Turrisi, A; Graziano, S; Williams, T; Zhang, C; Vokes, EE; Green, MR. Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study--CALGB 9534. Clinical Lung Cancer. 2005;7:47-53.  Abstract
  • Clamon, G; Herndon, J; Kern, J; Govindan, R; Garst, J; Watson, D; Green Cancer, M; Leukemia Group, B. Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B. Cancer. 2005;103:1670-1675.  Abstract
  • D'Cunha, J; Herndon, JE; Herzan, DL; Patterson, GA; Kohman, LJ; Harpole, DH; Kernstine, KH; Kern, JA; Green, MR; Maddaus, MA; Kratzke, RA; Cancer and Leukemia Group B. Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: results from CALGB 9761, a prospective trial. Lung Cancer. 2005;48:241-246.  Abstract
  • Dresler, CM; Olak, J; Herndon, JE; Richards, WG; Scalzetti, E; Fleishman, SB; Kernstine, KH; Demmy, T; Jablons, DM; Kohman, L; Daniel, TM; Haasler, GB; Sugarbaker, DJ; Cooperative Groups Cancer and Leukemia Group B, ; Eastern Cooperative Oncology Group, ; North Central Cooperative Oncology Group, ; Radiation Therapy Oncology Group. Phase III intergroup study of talc poudrage vs talc slurry sclerosis for malignant pleural effusion. Chest. 2005;127:909-915.  Abstract
  • Govindan, R; Kratzke, RA; Herndon, JE; Niehans, GA; Vollmer, R; Watson, D; Green, MR; Kindler, HL; Cancer and Leukemia Group B (CALGB 30101). Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Clinical Cancer Research. 2005;11:2300-2304.  Abstract
  • Hensley, ML; Dowell, J; Herndon, JE; Winer, E; Stark, N; Weeks, JC; Paskett, E. Economic outcomes of breast cancer survivorship: CALGB study 79804. Breast Cancer Research and Treatment. 2005;91:153-161.  Abstract
  • Joshi, MB; Shirota, Y; Danenberg, KD; Conlon, DH; Salonga, DS; Herndon, JE; Danenberg, PV; Harpole, DH. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clinical Cancer Research. 2005;11:2215-2221.  Abstract
  • Kelley, MJ; Glaser, EM; Herndon, JE; Becker, F; Bhagat, R; Zhang, YJ; Santella, RM; Carmella, SG; Hecht, SS; Gallot, L; Schilder, L; Crowell, JA; Perloff, M; Folz, RJ; Bergan, RC. Safety and efficacy of weekly oral oltipraz in chronic smokers. Cancer Epidemiology, Biomarkers and Prevention. 2005;14:892-899.  Abstract
  • Kim, YH; Marom, EM; Herndon, JE; McAdams, HP. Pulmonary vein diameter, cross-sectional area, and shape: CT analysis. Radiology. 2005;235:43-49.  Abstract
  • Kindler, HL; Herndon, JE; Zhang, C; Green, MR; Cancer and Leukemia Group B. Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B. Lung Cancer. 2005;48:423-428.  Abstract
  • Lamont, EB; Herndon, JE; Weeks, JC; Henderson, IC; Lilenbaum, R; Schilsky, RL; Christakis, NA. Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. Journal of National Cancer Institute. 2005;97:1080-1083.  Abstract
  • Leitch, AM; Beitsch, PD; McCall, LM; Posther, K; Newman, LA; Herndon, JE; Hunt, KK; Giuliano, AE. Patterns of participation and successful patient recruitment to American College of Surgeons Oncology Group Z0010, a phase II trial for patients with early-stage breast cancer. The American Journal of Surgery. 2005;190:539-542.  Abstract
  • Lilenbaum, RC; Herndon, JE; List, MA; Desch, C; Watson, DM; Miller, AA; Graziano, SL; Perry, MC; Saville, W; Chahinian, P; Weeks, JC; Holland, JC; Green, MR. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). Journal of Clinical Oncology. 2005;23:190-196.  Abstract
  • McClay, EF; Bogart, J; Herndon, JE; Watson, D; Evans, L; Seagren, SL; Green, MR; Cancer and Leukemia Group B Study (9235). A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235). American Journal of Clinical Oncology: cancer clinical trials. 2005;28:81-90.  Abstract
  • McLendon, RE; Herndon, JE; West, B; Reardon, D; Wiltshire, R; Rasheed, BK; Quinn, J; Friedman, HS; Friedman, AH; Bigner, DD. Survival analysis of presumptive prognostic markers among oligodendrogliomas. Cancer. 2005;104:1693-1699.  Abstract
  • Miller, AA; Herndon, JE; Gu, L; Green, MR; Cancer and Leukemia Group B. Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004). Lung Cancer. 2005;48:399-407.  Abstract
  • Niell, HB; Herndon, JE; Miller, AA; Watson, DM; Sandler, AB; Kelly, K; Marks, RS; Perry, MC; Ansari, RH; Otterson, G; Ellerton, J; Vokes, EE; Green, MR; Cancer and Leukemia Group. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. Journal of Clinical Oncology. 2005;23:3752-3759.  Abstract
  • Peppercorn, J; Herndon, J; Kornblith, AB; Peters, W; Ahles, T; Vredenburgh, J; Schwartz, G; Shpall, E; Hurd, DD; Holland, J; Winer, E. Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066. Cancer. 2005;104:1580-1589.  Abstract
  • Posther, KE; McCall, LM; Blumencranz, PW; Burak, WE; Beitsch, PD; Hansen, NM; Morrow, M; Wilke, LG; Herndon, JE; Hunt, KK; Giuliano, AE. Sentinel node skills verification and surgeon performance: data from a multicenter clinical trial for early-stage breast cancer. Annals of Surgery. 2005;242:593-599.  Abstract
  • Quinn, JA; Desjardins, A; Weingart, J; Brem, H; Dolan, ME; Delaney, SM; Vredenburgh, J; Rich, J; Friedman, AH; Reardon, DA; Sampson, JH; Pegg, AE; Moschel, RC; Birch, R; McLendon, RE; Provenzale, JM; Gururangan, S; Dancey, JE; Maxwell, J; Tourt-Uhlig, S; Herndon, JE; Bigner, DD; Friedman, HS. Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. Journal of Clinical Oncology. 2005;23:7178-7187.  Abstract
  • Reardon, DA; Egorin, MJ; Quinn, JA; Rich, JN; Gururangan, S; Vredenburgh, JJ; Desjardins, A; Sathornsumetee, S; Provenzale, JM; Herndon, JE; Dowell, JM; Badruddoja, MA; McLendon, RE; Lagattuta, TF; Kicielinski, KP; Dresemann, G; Sampson, JH; Friedman, AH; Salvado, AJ; Friedman, HS. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. Journal of Clinical Oncology. 2005;23:9359-9368.  Abstract
  • Reardon, DA; Quinn, JA; Rich, JN; Desjardins, A; Vredenburgh, J; Gururangan, S; Sathornsumetee, S; Badruddoja, M; McLendon, R; Provenzale, J; Herndon, JE; Dowell, JM; Burkart, JL; Newton, HB; Friedman, AH; Friedman, HS. Phase I trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer. 2005;104:1478-1486.  Abstract
  • Reardon, DA; Quinn, JA; Vredenburgh, J; Rich, JN; Gururangan, S; Badruddoja, M; Herndon, JE; Dowell, JM; Friedman, AH; Friedman, HS. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma. Cancer. 2005;103:329-338.  Abstract
  • Shennib, H; Bogart, J; Herndon, JE; Kohman, L; Keenan, R; Green, M; Sugarbaker, D; Cancer and Leukemia Group B, ; Eastern Cooperative Oncology Group. Video-assisted wedge resection and local radiotherapy for peripheral lung cancer in high-risk patients: the Cancer and Leukemia Group B (CALGB) 9335, a phase II, multi-institutional cooperative group study. Journal of Thoracic and Cardiovascular Surgery. 2005;129:813-818.  Abstract
  • Ahles, TA; Herndon, JE; Small, EJ; Vogelzang, NJ; Kornblith, AB; Ratain, MJ; Stadler, W; Palchak, D; Marshall, ME; Wilding, G; Petrylak, D; Holland, JC; Cancer and Leukemia Group B. Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480. Cancer. 2004;101:2202-2208.  Abstract
  • Bogart, JA; Herndon, JE; Lyss, AP; Watson, D; Miller, AA; Lee, ME; Turrisi, AT; Green, MR; Cancer and Leukemia Group B study 39808. 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. International Journal of Radiation: Oncology - Biology - Physics. 2004;59:460-468.  Abstract
  • Cheran, SK; Herndon, JE; Patz, EF. Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. Lung Cancer. 2004;44:317-325.  Abstract
  • Gururangan, S; Hwang, E; Herndon, JE; Fuchs, H; George, T; Coleman, RE. [18F]fluorodeoxyglucose-positron emission tomography in patients with medulloblastoma. Neurosurgery. 2004;55:1280-1288.  Abstract
  • Howard, BA; Zheng, Z; Campa, MJ; Wang, MZ; Sharma, A; Haura, E; Herndon, JE; Fitzgerald, MC; Bepler, G; Patz, EF. "Translating Biomarkers into Clinical Practice: Prognostic Implications of Cyclophilin A and Macrophage Migration Inhibitory Factor Identified from Protein Expression Profiles in Non-Small Cell Lung Cancer". 2004;46:313-323.  Abstract
  • Johnson, E; Lake, D; Herndon, JE; Box, JW; Lynch, TJ; Green, MR. Phase II trial of vinorelbine plus doxorubicin in relapsed small-cell lung cancer: CALGB 9332. American Journal of Clinical Oncology: cancer clinical trials. 2004;27:19-23.  Abstract
  • Marks, LB; Garst, J; Socinski, MA; Sibley, G; Blackstock, AW; Herndon, JE; Zhou, S; Shafman, T; Tisch, A; Clough, R; Yu, X; Turrisi, A; Anscher, M; Crawford, J; Rosenman, J; Carolina Conformal Therapy Consortium. Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium. Journal of Clinical Oncology. 2004;22:4329-4340.  Abstract
  • Marom, EM; Herndon, JE; Kim, YH; McAdams, HP. Variations in pulmonary venous drainage to the left atrium: implications for radiofrequency ablation. Radiology. 2004;230:824-829.  Abstract
  • McLendon, RE; Rasheed, A; Wiltshire, R; Herndon, J. Correlation of 1p-19q-defects in human gliomas with the light microscopic appearance of oligodendroglioma. Modern Pathology. 2004;17:604-605.  Abstract
  • Otterson, GA; Herndon, JE; Watson, D; Green, MR; Kindler, HL; Cancer and Leukemia Group B. Capecitabine in malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B (39807). Lung Cancer. 2004;44:251-259.  Abstract
  • Patz, EF; Swensen, SJ; Herndon, JE. Estimate of lung cancer mortality from low-dose spiral computed tomography screening trials: implications for current mass screening recommendations. Journal of Clinical Oncology. 2004;22:2202-2206.  Abstract
  • Quinn, JA; Reardon, DA; Friedman, AH; Rich, JN; Sampson, JH; Vredenburgh, J; Gururangan, S; Provenzale, JM; Walker, A; Schweitzer, H; Bigner, DD; Tourt-Uhlig, S; Herndon, JE; Affronti, ML; Jackson, S; Allen, D; Ziegler, K; Bohlin, C; Lentz, C; Friedman, HS. Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant glioma. Neuro-Oncology. 2004;6:145-153.  Abstract
  • Reardon, DA; Quinn, JA; Rich, JN; Gururangan, S; Vredenburgh, J; Sampson, JH; Provenzale, JM; Walker, A; Badruddoja, M; Tourt-Uhlig, S; Herndon, JE; Dowell, JM; Affronti, ML; Jackson, S; Allen, D; Ziegler, K; Silverman, S; Bohlin, C; Friedman, AH; Bigner, DD; Friedman, HS. Phase 2 trial of BCNU plus irinotecan in adults with malignant glioma. Neuro-Oncology. 2004;6:134-144.  Abstract
  • Rich, JN; Reardon, DA; Peery, T; Dowell, JM; Quinn, JA; Penne, KL; Wikstrand, CJ; Van Duyn, LB; Dancey, JE; McLendon, RE; Kao, JC; Stenzel, TT; Ahmed Rasheed, BK; Tourt-Uhlig, SE; Herndon, JE; Vredenburgh, JJ; Sampson, JH; Friedman, AH; Bigner, DD; Friedman, HS. Phase II trial of gefitinib in recurrent glioblastoma. Journal of Clinical Oncology. 2004;22:133-142.  Abstract
  • Rocha Lima, CM; Rizvi, NA; Zhang, C; Herndon, JE; Crawford, J; Govindan, R; King, GW; Green, MR; Cancer Leukemia Group B. Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC. Annals of Oncology. 2004;15:410-418.  Abstract
  • Sherman, CA; Herndon, JE; Watson, DM; Green, MR; Cancer and Leukemia Group B. A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung cancer. Lung Cancer. 2004;45:387-392.  Abstract
  • Socinski, MA; Zhang, C; Herndon, JE; Dillman, RO; Clamon, G; Vokes, E; Akerley, W; Crawford, J; Perry, MC; Seagren, SL; Green, MR. Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity. Annals of Oncology. 2004;15:1033-1041.  Abstract
  • Wiltshire, RN; Herndon, JE; Lloyd, A; Friedman, HS; Bigner, DD; Bigner, SH; McLendon, RE. Comparative genomic hybridization analysis of astrocytomas: prognostic and diagnostic implications. The Journal of Molecular Diagnostics. 2004;6:166-179.  Abstract
  • Akerley, W; Herndon, JE; Egorin, MJ; Lyss, AP; Kindler, HL; Savarese, DM; Sherman, CA; Rosen, DM; Hollis, D; Ratain, MJ; Green, MR. Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. Cancer. 2003;97:2480-2486.  Abstract
  • Anscher, MS; Marks, LB; Shafman, TD; Clough, R; Huang, H; Tisch, A; Munley, M; Herndon, JE; Garst, J; Crawford, J; Jirtle, RL. Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy. International Journal of Radiation: Oncology - Biology - Physics. 2003;56:988-995.  Abstract
  • Bernacki, SH; Stankovic, AK; Williams, LO; Beck, JC; Herndon, JE; Snow-Bailey, K; Prior, TW; Matteson, KJ; Wasserman, LM; Cole, EC; Stenzel, TT. Establishment of stably EBV-transformed cell lines from residual clinical blood samples for use in performance evaluation and quality assurance in molecular genetic testing. The Journal of Molecular Diagnostics. 2003;5:227-230.  Abstract
  • Brooks, KR; To, K; Joshi, MB; Conlon, DH; Herndon, JE; D'Amico, TA; Harpole, DH. Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection. Annals of Thoracic Surgery. 2003;76:187-193.  Abstract
  • Gururangan, S; McLaughlin, C; Quinn, J; Rich, J; Reardon, D; Halperin, EC; Herndon, J; Fuchs, H; George, T; Provenzale, J; Watral, M; McLendon, RE; Friedman, A; Friedman, HS; Kurtzberg, J; Vredenbergh, J; Martin, PL. High-dose chemotherapy with autologous stem-cell rescue in children and adults with newly diagnosed pineoblastomas. Journal of Clinical Oncology. 2003;21:2187-2191.  Abstract
  • Kornblith, AB; Herndon, JE; Weiss, RB; Zhang, C; Zuckerman, EL; Rosenberg, S; Mertz, M; Payne, D; Jane Massie, M; Holland, JF; Wingate, P; Norton, L; Holland, JC. Long-term adjustment of survivors of early-stage breast carcinoma, 20 years after adjuvant chemotherapy. Cancer. 2003;98:679-689.  Abstract
  • Marom, EM; Palmer, SM; Erasmus, JJ; Herndon, JE; Zhang, C; McAdams, HP. Pleural effusions in lung transplant recipients: image-guided small-bore catheter drainage. Radiology. 2003;228:241-245.  Abstract
  • Quinn, JA; Reardon, DA; Friedman, AH; Rich, JN; Sampson, JH; Provenzale, JM; McLendon, RE; Gururangan, S; Bigner, DD; Herndon, JE; Avgeropoulos, N; Finlay, J; Tourt-Uhlig, S; Affronti, ML; Evans, B; Stafford-Fox, V; Zaknoen, S; Friedman, HS. Phase II trial of temozolomide in patients with progressive low-grade glioma. Journal of Clinical Oncology. 2003;21:646-651.  Abstract
  • Sampson, JH; Akabani, G; Archer, GE; Bigner, DD; Berger, MS; Friedman, AH; Friedman, HS; Herndon, JE; Kunwar, S; Marcus, S; McLendon, RE; Paolino, A; Penne, K; Provenzale, J; Quinn, J; Reardon, DA; Rich, J; Stenzel, T; Tourt-Uhlig, S; Wikstrand, C; Wong, T; Williams, R; Yuan, F; Zalutsky, MR; Pastan, I. Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-alpha and a mutated form of the Pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. Journal of Neuro-Oncology. 2003;65:27-35.  Abstract
  • Vollmer, RT; Herndon, JE; D'Cunha, J; Abraham, NZ; Solberg, J; Fatourechi, M; Maruska, A; Kern, JA; Green, MR; Kratzke, RA; Maddaus, MA; Cancer and Leukemia Group B Trial 9761. Immunohistochemical detection of occult lymph node metastases in non-small cell lung cancer: anatomical pathology results from Cancer and Leukemia Group B Trial 9761. Clinical Cancer Research. 2003;9:5630-5635.  Abstract
  • Blackstock, AW; Herndon, JE; Paskett, ED; Perry, MC; Graziano, SL; Muscato, JJ; Kosty, MP; Akerley, WL; Holland, J; Fleishman, S; Green, MR. Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B. Journal of the National Cancer Institute. 2002;94:284-290.  Abstract
  • D'Cunha, J; Corfits, AL; Herndon, JE; Kern, JA; Kohman, LJ; Patterson, GA; Kratzke, RA; Maddaus, MA. Molecular staging of lung cancer: real-time polymerase chain reaction estimation of lymph node micrometastatic tumor cell burden in stage I non-small cell lung cancer--preliminary results of Cancer and Leukemia Group B Trial 9761. Journal of Thoracic and Cardiovascular Surgery. 2002;123:484-491.  Abstract
  • Elias, AD; Kumar, P; Herndon, J; Skarin, AT; Sugarbaker, DJ; Green, MR. Radiotherapy versus chemotherapy plus radiotherapy in surgically treated IIIA N2 non-small-cell lung cancer. Clinical Lung Cancer. 2002;4:95-103.  Abstract
  • Gururangan, S; Cavazos, CM; Ashley, D; Herndon, JE; Bruggers, CS; Moghrabi, A; Scarcella, DL; Watral, M; Tourt-Uhlig, S; Reardon, D; Friedman, HS. Phase II study of carboplatin in children with progressive low-grade gliomas. Journal of Clinical Oncology. 2002;20:2951-2958.  Abstract
  • Johnson, EA; Klimstra, DS; Herndon, JE; Catalano, E; Canellos, GP; Graziano, SL; Kern, JA; Green, MR. Aberrant p53 staining does not predict cisplatin resistance in locally advanced non-small cell lung cancer. Cancer Investigation. 2002;20:686-692.  Abstract
  • Kornblith, AB; Herndon, JE; Silverman, LR; Demakos, EP; Odchimar-Reissig, R; Holland, JF; Powell, BL; DeCastro, C; Ellerton, J; Larson, RA; Schiffer, CA; Holland, JC. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. Journal of Clinical Oncology. 2002;20:2441-2452.  Abstract
  • Lyss, AP; Herndon, JE; Lynch, TJ; Turrisi, AT; Watson, DM; Grethlein, SJ; Green, MR. Novel doublets in extensive-stage small-cell lung cancer: a randomized phase II study of topotecan plus cisplatin or paclitaxel (CALGB 9430). Clinical Lung Cancer. 2002;3:205-210.  Abstract
  • Marom, EM; Erasmus, JJ; Herndon, JE; Zhang, C; McAdams, HP. Usefulness of imaging-guided catheter drainage and talc sclerotherapy in patients with metastatic gynecologic malignancies and symptomatic pleural effusions. American Journal of Roentgenology. 2002;179:105-108.  Abstract
  • Marom, EM; Sarvis, S; Herndon, JE; Patz, EF. T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET. Radiology. 2002;223:453-459.  Abstract
  • Naughton, MJ; Herndon, JE; Shumaker, SA; Miller, AA; Kornblith, AB; Chao, D; Holland, J. The health-related quality of life and survival of small-cell lung cancer patients: results of a companion study to CALGB 9033. Quality of Life Research. 2002;11:235-248.  Abstract
  • Quinn, JA; Pluda, J; Dolan, ME; Delaney, S; Kaplan, R; Rich, JN; Friedman, AH; Reardon, DA; Sampson, JH; Colvin, OM; Haglund, MM; Pegg, AE; Moschel, RC; McLendon, RE; Provenzale, JM; Gururangan, S; Tourt-Uhlig, S; Herndon, JE; Bigner, DD; Friedman, HS. Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. Journal of Clinical Oncology. 2002;20:2277-2283.  Abstract
  • Rasheed, A; Herndon, JE; Stenzel, TT; Raetz, JG; Kendelhardt, J; Friedman, HS; Friedman, AH; Bigner, DD; Bigner, SH; McLendon, RE. Molecular markers of prognosis in astrocytic tumors. Cancer. 2002;94:2688-2697.  Abstract
  • Reardon, DA; Akabani, G; Coleman, RE; Friedman, AH; Friedman, HS; Herndon, JE; Cokgor, I; McLendon, RE; Pegram, CN; Provenzale, JM; Quinn, JA; Rich, JN; Regalado, LV; Sampson, JH; Shafman, TD; Wikstrand, CJ; Wong, TZ; Zhao, XG; Zalutsky, MR; Bigner, DD. Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. Journal of Clinical Oncology. 2002;20:1389-1397.  Abstract
  • Rocha Lima, CM; Herndon, JE; Kosty, M; Clamon, G; Green, MR. Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B. Cancer. 2002;94:181-187.  Abstract
  • Vokes, EE; Herndon, JE; Crawford, J; Leopold, KA; Perry, MC; Miller, AA; Green, MR. Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. Journal of Clinical Oncology. 2002;20:4191-4198.  Abstract
  • Aloia, T; Bepler, G; Harpole, D; Goodman, PC; McAdams, HP; Erasmus, JJ; Herndon, JE; Patz, EF. Integration of peripheral blood biomarkers with computed tomography to differentiate benign from malignant pulmonary opacities. Cancer Epidemiology: the international journal of cancer epidemiology, detection and prevention. 2001;25:336-343.  Abstract
  • Aloia, TA; Harpole, DH; Reed, CE; Allegra, C; Moore, MB; Herndon, JE; D'Amico, TA. Tumor marker expression is predictive of survival in patients with esophageal cancer. Annals of Thoracic Surgery. 2001;72:859-866.  Abstract
  • Anscher, MS; Marks, LB; Shafman, TD; Clough, R; Huang, H; Tisch, A; Munley, M; Herndon, JE; Garst, J; Crawford, J; Jirtle, RL. Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation. Journal of Clinical Oncology. 2001;19:3758-3765.  Abstract
  • Cameron, CL; Cella, D; Herndon, JE; Kornblith, AB; Zuckerman, E; Henderson, E; Weiss, RB; Cooper, MR; Silver, RT; Leone, L; Canellos, GP; Peterson, BA; Holland, JC. Persistent symptoms among survivors of Hodgkin's disease: an explanatory model based on classical conditioning. Health Psychology. 2001;20:71-75.  Abstract
  • D'Amico, TA; Aloia, TA; Moore, MB; Conlon, DH; Herndon, JE; Kinch, MS; Harpole, DH. Predicting the sites of metastases from lung cancer using molecular biologic markers. Annals of Thoracic Surgery. 2001;72:1144-1148.  Abstract
  • Graziano, SL; Tatum, A; Herndon, JE; Box, J; Memoli, V; Green, MR; Kern, JA. Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study. Lung Cancer. 2001;33:115-123.  Abstract
  • Gururangan, S; Cokgor, L; Rich, JN; Edwards, S; Affronti, ML; Quinn, JA; Herndon, JE; Provenzale, JM; McLendon, RE; Tourt-Uhlig, S; Sampson, JH; Stafford-Fox, V; Zaknoen, S; Early, M; Friedman, AH; Friedman, HS. Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. Neuro-Oncology. 2001;3:246-250.  Abstract
  • Harpole, DH; Moore, MB; Herndon, JE; Aloia, T; D'Amico, TA; Sporn, T; Parr, A; Linoila, I; Allegra, C. The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. Clinical Cancer Research. 2001;7:562-569.  Abstract
  • Heyneman, LE; Herndon, JE; Goodman, PC; Patz, EF. Stage distribution in patients with a small (< or = 3 cm) primary nonsmall cell lung carcinoma. Implication for lung carcinoma screening. Cancer. 2001;92:3051-3055.  Abstract
  • Kindler, HL; Millard, F; Herndon, JE; Vogelzang, NJ; Suzuki, Y; Green, MR. Gemcitabine for malignant mesothelioma: A phase II trial by the Cancer and Leukemia Group B. Lung Cancer. 2001;31:311-317.  Abstract
  • Kornblith, AB; Herndon, JE; Zuckerman, E; Godley, PA; Savarese, D; Vogelzang, NJ; Cancer and Leukemia Group B (CALGB). The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study. Annals of Oncology. 2001;12:633-641.  Abstract
  • Kornblith, AB; Herndon, JE; Zuckerman, E; Viscoli, CM; Horwitz, RI; Cooper, MR; Harris, L; Tkaczuk, KH; Perry, MC; Budman, D; Norton, LC; Holland, J; Cancer and Leukemia Group B. Social support as a buffer to the psychological impact of stressful life events in women with breast cancer. Cancer. 2001;91:443-454.  Abstract
  • Kosty, MP; Herndon, JE; Vogelzang, NJ; Kindler, HL; Green, MR. High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631. Lung Cancer. 2001;34:289-295.  Abstract
  • Maguire, PD; Marks, LB; Sibley, GS; Herndon, JE; Clough, RW; Light, KL; Hernando, ML; Antoine, PA; Anscher, MS. 73.6 Gy and beyond: hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer. Journal of Clinical Oncology. 2001;19:705-711.  Abstract
  • Marom, EM; Aloia, TA; Moore, MB; Hara, M; Herndon, JE; Harpole, DH; Goodman, PC; Patz, EF. Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer. Lung Cancer. 2001;33:99-107.  Abstract
  • Niell, HB; Perry, MC; Clamon, G; Crawford, J; Miller, AA; Herndon, J; Green, MR. Carboplatin/etoposide/paclitaxel in the treatment of patients with extensive small-cell lung cancer. Clinical Lung Cancer. 2001;2:204-209.  Abstract
  • Salgia, R; Harpole, D; Herndon, JE; Pisick, E; Elias, A; Skarin, AT. Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer. Anticancer Research: international journal of cancer research and treatment. 2001;21:1241-1246.  Abstract
  • Socinski, MA; Marks, LB; Garst, J; Sibley, GS; Blackstock, W; Turrisi, A; Herndon, J; Zhou, S; Anscher, M; Crawford, J; Shafman, T; Rosenman, J. Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: a preliminary report of a phase I dose escalation trial from the Carolina Conformal Therapy Consortium. The Oncologist. 2001;6 Suppl 1:20-24.  Abstract
  • Akabani, G; Cokgor, I; Coleman, RE; González Trotter, D; Wong, TZ; Friedman, HS; Friedman, AH; Garcia-Turner, A; Herndon, JE; DeLong, D; McLendon, RE; Zhao, XG; Pegram, CN; Provenzale, JM; Bigner, DD; Zalutsky, MR. Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. International Journal of Radiation: Oncology - Biology - Physics. 2000;46:947-958.  Abstract
  • Cokgor, I; Akabani, G; Kuan, CT; Friedman, HS; Friedman, AH; Coleman, RE; McLendon, RE; Bigner, SH; Zhao, XG; Garcia-Turner, AM; Pegram, CN; Wikstrand, CJ; Shafman, TD; Herndon, JE; Provenzale, JM; Zalutsky, MR; Bigner, DD. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas. Journal of Clinical Oncology. 2000;18:3862-3872.  Abstract
  • D'Amico, TA; Aloia, TA; Moore, MB; Herndon, JE; Brooks, KR; Lau, CL; Harpole, DH. Molecular biologic substaging of stage I lung cancer according to gender and histology. Annals of Thoracic Surgery. 2000;69:882-886.  Abstract
  • Farrell, MA; McAdams, HP; Herndon, JE; Patz, EF. Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease. Radiology. 2000;215:886-890.  Abstract
  • Friedman, HS; Pluda, J; Quinn, JA; Ewesuedo, RB; Long, L; Friedman, AH; Cokgor, I; Colvin, OM; Haglund, MM; Ashley, DM; Rich, JN; Sampson, J; Pegg, AE; Moschel, RC; McLendon, RE; Provenzale, JM; Stewart, ES; Tourt-Uhlig, S; Garcia-Turner, AM; Herndon, JE; Bigner, DD; Dolan, ME. Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. Journal of Clinical Oncology. 2000;18:3522-3528.  Abstract
  • Patz, EF; Connolly, J; Herndon, J. Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer. American Journal of Roentgenology. 2000;174:769-774.  Abstract
  • Patz, EF; Rossi, S; Harpole, DH; Herndon, JE; Goodman, PC. Correlation of tumor size and survival in patients with stage IA non-small cell lung cancer. Chest. 2000;117:1568-1571.  Abstract
  • Perry, MC; Ihde, DC; Herndon, JE; Grossbard, ML; Grethein, SJ; Atkins, JN; Vokes, EE; Green, MR. Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532. Lung Cancer. 2000;28:63-68.  Abstract
  • Clamon, G; Herndon, J; Cooper, R; Chang, AY; Rosenman, J; Green, MR. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. Journal of Clinical Oncology. 1999;17:4-11.  Abstract
  • D'Amico, TA; Massey, M; Herndon, JE; Moore, MB; Harpole, DH. A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. Journal of Thoracic and Cardiovascular Surgery. 1999;117:736-743.  Abstract
  • Hara, M; McAdams, HP; Vredenburgh, JJ; Herndon, JE; Patz, EF. Thymic hyperplasia after high-dose chemotherapy and autologous stem cell transplantation: incidence and significance in patients with breast cancer. American Journal of Roentgenology. 1999;173:1341-1344.  Abstract
  • Herndon, JE; Fleishman, S; Kornblith, AB; Kosty, M; Green, MR; Holland, J. Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma?. Cancer. 1999;85:333-340.  Abstract
  • Kindler, HL; Belani, CP; Herndon, JE; Vogelzang, NJ; Suzuki, Y; Green, MR. Edatrexate (10-ethyl-deaza-aminopterin) (NSC #626715) with or without leucovorin rescue for malignant mesothelioma. Sequential phase II trials by the cancer and leukemia group B. Cancer. 1999;86:1985-1991.  Abstract
  • Maguire, PD; Sibley, GS; Zhou, SM; Jamieson, TA; Light, KL; Antoine, PA; Herndon, JE; Anscher, MS; Marks, LB. Clinical and dosimetric predictors of radiation-induced esophageal toxicity. International Journal of Radiation: Oncology - Biology - Physics. 1999;45:97-103.  Abstract
  • Marom, EM; McAdams, HP; Erasmus, JJ; Goodman, PC; Culhane, DK; Coleman, RE; Herndon, JE; Patz, EF. Staging non-small cell lung cancer with whole-body PET. Radiology. 1999;212:803-809.  Abstract
  • Marom, EM; Patz, EF; Erasmus, JJ; McAdams, HP; Goodman, PC; Herndon, JE. Malignant pleural effusions: treatment with small-bore-catheter thoracostomy and talc pleurodesis. Radiology. 1999;210:277-281.  Abstract
  • Patz, EF; Erasmus, JJ; McAdams, HP; Connolly, JE; Marom, EM; Goodman, PC; Leder, RA; Keogan, MT; Herndon, JE. Lung cancer staging and management: comparison of contrast-enhanced and nonenhanced helical CT of the thorax. Radiology. 1999;212:56-60.  Abstract
  • Shieh, DB; Godleski, J; Herndon, JE; Azuma, T; Mercer, H; Sugarbaker, DJ; Kwiatkowski, DJ. Cell motility as a prognostic factor in Stage I nonsmall cell lung carcinoma: the role of gelsolin expression. Cancer. 1999;85:47-57.  Abstract
  • Steele, GD; Herndon, JE; Bleday, R; Russell, A; Benson, A; Hussain, M; Burgess, A; Tepper, JE; Mayer, RJ. Sphincter-sparing treatment for distal rectal adenocarcinoma. Annals of Surgical Oncology. 1999;6:433-441.  Abstract
  • Vogelzang, NJ; Herndon, JE; Miller, A; Strauss, G; Clamon, G; Stewart, FM; Aisner, J; Lyss, A; Cooper, MR; Suzuki, Y; Green, MR. High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234. Annals of Oncology. 1999;10:597-600.  Abstract
  • Ahles, TA; Silberfarb, PM; Herndon, J; Maurer, LH; Kornblith, AB; Aisner, J; Perry, MC; Eaton, WL; Zacharski, LL; Green, MR; Holland, JC. Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: a study by the Cancer and Leukemia Group B. Journal of Clinical Oncology. 1998;16:1954-1960.  Abstract
  • Ahuja, V; Coleman, RE; Herndon, J; Patz, EF. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer. 1998;83:918-924.  Abstract
  • Assi, Z; Caruso, JL; Herndon, J; Patz, EF. Cytologically proved malignant pleural effusions: distribution of transudates and exudates. Chest. 1998;113:1302-1304.  Abstract
  • Bigner, DD; Brown, MT; Friedman, AH; Coleman, RE; Akabani, G; Friedman, HS; Thorstad, WL; McLendon, RE; Bigner, SH; Zhao, XG; Pegram, CN; Wikstrand, CJ; Herndon, JE; Vick, NA; Paleologos, N; Cokgor, I; Provenzale, JM; Zalutsky, MR. Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: phase I trial results. Journal of Clinical Oncology. 1998;16:2202-2212.  Abstract
  • Choi, NC; Herndon, JE; Rosenman, J; Carey, RW; Chung, CT; Bernard, S; Leone, L; Seagren, S; Green, M. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. Journal of Clinical Oncology. 1998;16:3528-3536.  Abstract
  • Clamon, G; Herndon, J; Akerley, W; Green, M. Subcutaneous interleukin-2 as initial therapy for patients with extensive small cell lung cancer: a phase II trial of Cancer and Leukemia Group B. Lung Cancer. 1998;19:25-29.  Abstract
  • Friedman, HS; Kokkinakis, DM; Pluda, J; Friedman, AH; Cokgor, I; Haglund, MM; Ashley, DM; Rich, J; Dolan, ME; Pegg, AE; Moschel, RC; McLendon, RE; Kerby, T; Herndon, JE; Bigner, DD; Schold, SC. Phase I trial of O6-benzylguanine for patients undergoing surgery for malignant glioma. Journal of Clinical Oncology. 1998;16:3570-3575.  Abstract
  • Graham, ML; Asselin, BL; Herndon, JE; Casey, JR; Chaffee, S; Ciocci, GH; Daeschner, CW; Davis, AR; Gold, S; Halperin, EC; Laughlin, MJ; Martin, PL; Olson, JF; Kurtzberg, J. Toxicity, pharmacology and feasibility of administration of PEG-L-asparaginase as consolidation therapy in patients undergoing bone marrow transplantation for acute lymphoblastic leukemia. Bone Marrow Transplantation. 1998;21:879-885.  Abstract
  • Graziano, SL; Kern, JA; Herndon, JE; Tatum, A; Brisson, ML; Memoli, V; Sugarbaker, D; Skarin, AT; Kreisman, H; Green, MR. Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: a Cancer and Leukemia Group B study. Lung Cancer. 1998;21:203-211.  Abstract
  • Herndon, JE. A design alternative for two-stage, phase II, multicenter cancer clinical trials. Contemporary Clinical Trials. 1998;19:440-450.  Abstract
  • Herndon, JE; Green, MR; Chahinian, AP; Corson, JM; Suzuki, Y; Vogelzang, NJ. Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998;113:723-731.  Abstract
  • Kornblith, AB; Herndon, JE; Zuckerman, E; Cella, DF; Cherin, E; Wolchok, S; Weiss, RB; Diehl, LF; Henderson, E; Cooper, MR; Schiffer, C; Canellos, GP; Mayer, RJ; Silver, RT; Schilling, A; Peterson, BA; Greenberg, D; Holland, JC. Comparison of psychosocial adaptation of advanced stage Hodgkin's disease and acute leukemia survivors. Cancer and Leukemia Group B. Annals of Oncology. 1998;9:297-306.  Abstract
  • Kwiatkowski, DJ; Harpole, DH; Godleski, J; Herndon, JE; Shieh, DB; Richards, W; Blanco, R; Xu, HJ; Strauss, GM; Sugarbaker, DJ. Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. Journal of Clinical Oncology. 1998;16:2468-2477.  Abstract
  • Mehdi, SA; Perry, MC; Herndon, JE; Crawford, J; Young, R; Graziano, SL. A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer. Journal of Interferon and Cytokine Research. 1998;18:623-627.  Abstract
  • Patz, EF; McAdams, HP; Erasmus, JJ; Goodman, PC; Culhane, DK; Gilkeson, RC; Herndon, J. Sclerotherapy for malignant pleural effusions: a prospective randomized trial of bleomycin vs doxycycline with small-bore catheter drainage. Chest. 1998;113:1305-1311.  Abstract
  • Perry, MC; Herndon, JE; Eaton, WL; Green, MR. Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B Study 8083. Journal of Clinical Oncology. 1998;16:2466-2467.  Abstract
  • Ryan, CW; Herndon, J; Vogelzang, NJ. A review of chemotherapy trials for malignant mesothelioma. Chest. 1998;113:66S-73S.  Abstract
  • Samuels, BL; Herndon, JE; Harmon, DC; Carey, R; Aisner, J; Corson, JM; Suzuki, Y; Green, MR; Vogelzang, NJ. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B. Cancer. 1998;82:1578-1584.  Abstract
  • Erasmus, JJ; Patz, EF; McAdams, HP; Murray, JG; Herndon, J; Coleman, RE; Goodman, PC. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. American Journal of Roentgenology. 1997;168:1357-1360.  Abstract
  • Graham, ML; Herndon, JE; Casey, JR; Chaffee, S; Ciocci, GH; Krischer, JP; Kurtzberg, J; Laughlin, MJ; Longee, DC; Olson, JF; Paleologus, N; Pennington, CN; Friedman, HS. High-dose chemotherapy with autologous stem-cell rescue in patients with recurrent and high-risk pediatric brain tumors. Journal of Clinical Oncology. 1997;15:1814-1823.  Abstract
  • Greenberg, DB; Kornblith, AB; Herndon, JE; Zuckerman, E; Schiffer, CA; Weiss, RB; Mayer, RJ; Wolchok, SM; Holland, JC. Quality of life for adult leukemia survivors treated on clinical trials of Cancer and Leukemia Group B during the period 1971-1988: predictors for later psychologic distress. Cancer. 1997;80:1936-1944.  Abstract
  • Herndon, JE; Fleishman, S; Kosty, MP; Green, MR. A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931. Contemporary Clinical Trials. 1997;18:286-300.  Abstract
  • Luikart, SD; Herndon, JE; Hollis, DR; MacDonald, M; Maurer, LH; Crawford, J; Clamon, GH; Wright, J; Perry, MC; Ozer, H; Green, MR. Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung cancer: a Cancer and Leukemia Group B study (CALGB 8832). American Journal of Clinical Oncology: cancer clinical trials. 1997;20:24-30.  Abstract
  • Maurer, LH; Herndon, JE; Hollis, DR; Aisner, J; Carey, RW; Skarin, AT; Perry, MC; Eaton, WL; Zacharski, LL; Hammond, S; Green, MR. Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. Journal of Clinical Oncology. 1997;15:3378-3387.  Abstract
  • Vokes, EE; Leopold, KA; Herndon, J; Green, MR. Investigations of new drugs in combination with cisplatin in stage III non-small cell lung cancer. Seminars in Oncology. 1997;24:S8-42-S8-45.  Abstract
  • Yogelzang, NJ; Herndon, JE; Cirrincione, C; Harmon, DC; Antman, KH; Corson, JM; Suzuki, Y; Citron, ML; Green, MR. Dihydro-5-azacytidine in malignant mesothelioma. A phase II trial demonstrating activity accompanied by cardiac toxicity. Cancer and Leukemia Group B. Cancer. 1997;79:2237-2242.  Abstract
  • Brown, MT; Coleman, RE; Friedman, AH; Friedman, HS; McLendon, RE; Reiman, R; Felsberg, GJ; Tien, RD; Bigner, SH; Zalutsky, MR; Zhao, XG; Wikstrand, CJ; Pegram, CN; Herndon, JE; Vick, NA; Paleologos, N; Fredericks, RK; Schold, SC; Bigner, DD. Intrathecal 131I-labeled antitenascin monoclonal antibody 81C6 treatment of patients with leptomeningeal neoplasms or primary brain tumor resection cavities with subarachnoid communication: phase I trial results. Clinical Cancer Research. 1996;2:963-972.  Abstract
  • Dillman, RO; Herndon, J; Seagren, SL; Eaton, WL; Green, MR. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. Journal of the National Cancer Institute. 1996;88:1210-1215.  Abstract
  • Graziano, SL; Valone, FH; Herndon, JE; Crawford, J; Richards, F; Rege, VB; Clamon, G; Green, MR. A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study. Lung Cancer. 1996;14:315-329.  Abstract
  • Halperin, EC; Herndon, J; Schold, SC; Brown, M; Vick, N; Cairncross, JG; Macdonald, DR; Gaspar, L; Fischer, B; Dropcho, E; Rosenfeld, S; Morowitz, R; Piepmeier, J; Hait, W; Byrne, T; Salter, M; Imperato, J; Khandekar, J; Paleologos, N; Burger, P; Bentel, GC; Friedman, A. A phase III randomized prospective trial of external beam radiotherapy, mitomycin C, carmustine, and 6-mercaptopurine for the treatment of adults with anaplastic glioma of the brain. CNS Cancer Consortium. International Journal of Radiation: Oncology - Biology - Physics. 1996;34:793-802.  Abstract
  • Harpole, DH; Richards, WG; Herndon, JE; Sugarbaker, DJ. Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. Annals of Thoracic Surgery. 1996;61:1470-1476.  Abstract
  • Kumar, P; Herndon, J; Langer, M; Kohman, LJ; Elias, AD; Kass, FC; Eaton, WL; Seagren, SL; Green, MR; Sugarbaker, DJ. Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935. Cancer. 1996;77:2393-2399.  Abstract
  • Mitchell, EP; Perry, MC; Luikart, SD; Cirrincione, CT; Van Echo, DA; Herndon, JE; Maurer, LH; Clamon, G; Green, MR. A phase I/II trial of etoposide and cisplatin in extensive small cell lung cancer: a cancer and leukemia group B study. Lung Cancer. 1996;15:215-223.  Abstract
  • Tross, S; Herndon, J; Korzun, A; Kornblith, AB; Cella, DF; Holland, JF; Raich, P; Johnson, A; Kiang, DT; Perloff, M; Norton, L; Wood, W; Holland, JC. Psychological symptoms and disease-free and overall survival in women with stage II breast cancer. Cancer and Leukemia Group B. Journal of the National Cancer Institute. 1996;88:661-667.  Abstract
  • Bigner, DD; Archer, GE; McLendon, RE; Friedman, HS; Fuchs, HE; Pai, LH; Herndon, JE; Pastan, IH. Efficacy of compartmental administration of immunotoxin LMB-1 (B3-LysPE38) in a rat model of carcinomatous meningitis. Clinical Cancer Research. 1995;1:1545-1555.  Abstract
  • Bitran, JD; Green, M; Perry, M; Hollis, DR; Herndon, JE. A phase II study of recombinant interferon-gamma following combination chemotherapy for patients with extensive small cell lung cancer. CALGB. American Journal of Clinical Oncology: cancer clinical trials. 1995;18:67-70.  Abstract
  • Harpole, DH; Herndon, JE; Wolfe, WG; Iglehart, JD; Marks, JR. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. Cancer Research. 1995;55:51-56.  Abstract
  • Harpole, DH; Herndon, JE; Young, WG; Wolfe, WG; Sabiston, DC. Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence. Cancer. 1995;76:787-796.  Abstract
  • Harpole, DH; Marks, JR; Richards, WG; Herndon, JE; Sugarbaker, DJ. Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients. Clinical Cancer Research. 1995;1:659-664.  Abstract
  • Herndon, JE; Harrell, FE. The restricted cubic spline as baseline hazard in the proportional hazards model with step function time-dependent covariables. Statistics in Medicine. 1995;14:2119-2129.  Abstract
  • Kosty, MP; Herndon, JE; Green, MR; McIntyre, OR. Placebo-controlled randomized study of hydrazine sulfate in lung cancer. Journal of Clinical Oncology. 1995;13:1529-1530.  Abstract
  • Miller, AA; Herndon, JE; Hollis, DR; Ellerton, J; Langleben, A; Richards, F; Green, MR. Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. Journal of Clinical Oncology. 1995;13:1871-1879.  Abstract
  • Muscato, JJ; Cirrincione, C; Clamon, G; Perry, MC; Omura, G; Berkowitz, I; Reid, T; Herndon, JE; Green, MR. Etoposide (VP-16) and cisplatin at maximum tolerated dose in non-small cell lung carcinoma: a Cancer and Leukemia Group B study. Lung Cancer. 1995;13:285-294.  Abstract
  • Pastan, IH; Archer, GE; McLendon, RE; Friedman, HS; Fuchs, HE; Wang, QC; Pai, LH; Herndon, J; Bigner, DD. Intrathecal administration of single-chain immunotoxin, LMB-7 [B3(Fv)-PE38], produces cures of carcinomatous meningitis in a rat model. Proceedings of the National Academy of Sciences of USA. 1995;92:2765-2769.  Abstract
  • Patz, EF; Lowe, VJ; Goodman, PC; Herndon, J. Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma. Chest. 1995;108:1617-1621.  Abstract
  • Sugarbaker, DJ; Herndon, J; Kohman, LJ; Krasna, MJ; Green, MR. Results of cancer and leukemia group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group. Journal of Thoracic and Cardiovascular Surgery. 1995;109:473-483.  Abstract
  • Clamon, G; Herndon, J; Eaton, W; Rosenman, J; Maurer, LH; Cooper, MR; Green, MR. A feasibility study of extended chemotherapy for locally advanced non-small cell lung cancer: a phase II trial of cancer and leukemia group B. Cancer Investigation. 1994;12:273-282.  Abstract
  • Deutsch, M; Crawford, J; Leopold, K; Wolfe, W; Foster, W; Herndon, J; Blackwell, S; Yost, R. Phase II study of neoadjuvant chemotherapy and radiation therapy with thoracotomy in the treatment of clinically staged IIIA non-small cell lung cancer. Cancer. 1994;74:1243-1252.  Abstract
  • Green, MR; Kosty, MP; Muscato, JJ; Graziano, S; Dillman, RO; Clamon, GH; Herndon, J. Nonoperative management of non-small cell lung cancer: the current cancer and leukemia group B experience. Seminars in Oncology. 1994;21:60-65.  Abstract
  • Kosty, MP; Fleishman, SB; Herndon, JE; Coughlin, K; Kornblith, AB; Scalzo, A; Morris, JC; Mortimer, J; Green, MR. Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. Journal of Clinical Oncology. 1994;12:1113-1120.  Abstract
  • Rasheed, BK; McLendon, RE; Herndon, JE; Friedman, HS; Friedman, AH; Bigner, DD; Bigner, SH. Alterations of the TP53 gene in human gliomas. Cancer Research. 1994;54:1324-1330.  Abstract
  • Seagren, SL; Herndon, JE; Baeker, JR; Boles, M; Chung, C; Green, MR. Alternating irradiation and chemotherapy in stage III A and B nonsmall cell lung cancer: report of a cancer and Leukemia Group B phase II study 8636. International Journal of Radiation: Oncology - Biology - Physics. 1994;29:1085-1088.  Abstract
  • Vogelzang, NJ; Weissman, LB; Herndon, JE; Antman, KH; Cooper, MR; Corson, JM; Green, MR. Trimetrexate in malignant mesothelioma: A Cancer and Leukemia Group B Phase II study. Journal of Clinical Oncology. 1994;12:1436-1442.  Abstract
  • Wheeler, RH; Herndon, JE; Clamon, GH; Green, MR. A phase II study of recombinant beta-interferon at maximum tolerated dose in patients with advanced non-small cell lung cancer: a cancer and leukemia group B study. Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy. 1994;15:212-216.  Abstract
  • Chahinian, AP; Antman, K; Goutsou, M; Corson, JM; Suzuki, Y; Modeas, C; Herndon, JE; Aisner, J; Ellison, RR; Leone, L. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. Journal of Clinical Oncology. 1993;11:1559-1565.  Abstract
  • Clamon, G; Herndon, J; Perry, MC; Ozer, H; Kreisman, H; Maher, T; Ellerton, J; Green, MR. Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of Cancer and Leukemia Group B. Journal of the National Cancer Institute. 1993;85:316-320.  Abstract
  • Graziano, SL; Herndon, JE; Richards, F; DiFino, S; Modeas, C; Duggan, DB; Green, MR. A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study. Cancer. 1993;72:62-68.  Abstract
  • Halperin, EC; Gaspar, L; Imperato, J; Salter, M; Herndon, J; Dowling, S. An analysis of radiotherapy data from the CNS cancer consortium's randomized prospective trial comparing AZQ to BCNU in the treatment of patients with primary malignant brain tumors. The CNS cancer consortium. American Journal of Clinical Oncology: cancer clinical trials. 1993;16:277-283.  Abstract
  • Kornblith, AB; Hollis, DR; Zuckerman, E; Lyss, AP; Canellos, GP; Cooper, MR; Herndon, JE; Phillips, CA; Abrams, J; Aisner, J. Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. The Cancer and Leukemia Group B. Journal of Clinical Oncology. 1993;11:2081-2089.  Abstract
  • Schold, SC; Herndon, JE; Burger, PC; Halperin, EC; Vick, NA; Cairncross, JG; Macdonald, DR; Dropcho, EJ; Morawetz, R; Bigner, DD. Randomized comparison of diaziquone and carmustine in the treatment of adults with anaplastic glioma. Journal of Clinical Oncology. 1993;11:77-83.  Abstract
  • Lyss, AP; Perry, MC; Goutsou, M; Propert, K; Herndon, JE; Mason-Coughlin, K; Green, MR. Intensive etoposide and carboplatin chemotherapy for advanced non-small-cell lung cancer. A phase II trial of the Cancer and Leukemia Group B. American Journal of Clinical Oncology: cancer clinical trials. 1992;15:399-404.  Abstract
  • Panella, TJ; Smith, DC; Schold, SC; Rogers, MP; Winer, EP; Fine, RL; Crawford, J; Herndon, JE; Trump, DL. Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial. Cancer Research. 1992;52:2456-2459.  Abstract
  • Sketch, MH; Quigley, PJ; Perez, JA; Davidson, CJ; Muhlestein, JB; Herndon, JE; Glower, DD; Phillips, HR; Califf, RM; Stack, RS. Angiographic follow-up after internal mammary artery graft angioplasty. American Journal of Cardiology. 1992;70:401-403.  Abstract
  • Strauss, GM; Herndon, JE; Sherman, DD; Mathisen, DJ; Carey, RW; Choi, NC; Rege, VB; Modeas, C; Green, MR. Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. Journal of Clinical Oncology. 1992;10:1237-1244.  Abstract
  • Vokes, EE; Lyss, AP; Herndon, JE; Cooper, B; Perry, MC; Vinciguerra, V; Mason-Coughlin, K; Green, MR. Intravenous 6-thioguanine or cisplatin, fluorouracil and leucovorin for advanced non-small cell lung cancer: a randomized phase II study of the cancer and leukemia group B. Annals of Oncology. 1992;3:727-732.  Abstract
  • Davidoff, AM; Herndon, JE; Glover, NS; Kerns, BJ; Pence, JC; Iglehart, JD; Marks, JR. Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery. 1991;110:259-264.  Abstract
  • Doll, D; Goutsou, M; Graziano, S; Ellerton, J; Bitran, J; Modeas, C; Herndon, J; Perry, M; Green, M. Carboplatin and vinblastine in advanced non-small-cell lung cancer: a phase II study. Cancer Chemotherapy and Pharmacology. 1991;29:71-74.  Abstract
  • Glantz, MJ; Burger, PC; Herndon, JE; Friedman, AH; Cairncross, JG; Vick, NA; Schold, SC. Influence of the type of surgery on the histologic diagnosis in patients with anaplastic gliomas. Neurology. 1991;41:1741-1744.  Abstract
  • Glantz, MJ; Hoffman, JM; Coleman, RE; Friedman, AH; Hanson, MW; Burger, PC; Herndon, JE; Meisler, WJ; Schold, SC. Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography. Annals of Neurology. 1991;29:347-355.  Abstract
  • Nelson, CL; Herndon, JE; Mark, DB; Pryor, DB; Califf, RM; Hlatky, MA. Relation of clinical and angiographic factors to functional capacity as measured by the Duke Activity Status Index. American Journal of Cardiology. 1991;68:973-975.  Abstract